Enjoy complimentary customisation on priority with our Enterprise License!
Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein derivative responsible for producing erythrocytes in the body. When the endogenous production of EPO is disturbed, the normal RBC count can be restored by external supply of EPO-stimulating agents (ESAs). These agents are similar to the natural EPO in structure and function and are administered as injections. They can be produced by recombinant DNA technology and are used in the treatment of several diseases like anemia and cancer. With the rising prevalence of cancer worldwide, especially in China, the market for rhEPO is anticipated to have a positive outlook in the coming years. Chemotherapy is the first choice of treatment for cancer and the increasing prevalence of cancer will give rise to a significant number of cancer patients with chemotherapy-induced anemia. This is expected to propel the growth prospects for rhEPO drugs market in the coming years. According to the analysts at Technavio, the rhEPO drugs market in China will grow exponentially and will post a CAGR of close to 17% over the forecast period.
One of the emerging trends spurring the growth prospects for this market is the increasing penetration of rhEPO drugs in grade I and II hospitals across China. Most rhEPO drugs were being exclusively used in grade III hospitals, where specialized services to treat cancer and CKD are available. However, it has been observed that companies are striving to promote rhEPO drugs in grade I and II hospitals, which will increase the market share of rhEPO drugs in China during the forecast period.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Erythropoietin: An overview
PART 06: Global erythropoietin market
PART 07: China: Country snapshot
PART 08: Opportunities for pharmaceutical vendors in China
PART 09: Biopharmaceutical market in China
PART 10: Market landscape
PART 11: Market segmentation by end-user
PART 12: Market segmentation by application
PART 13: Drug pricing and reimbursement in China
PART 14: Pipeline portfolio
PART 15: Market drivers
PART 16: Impact of drivers
PART 17: Market challenges
PART 18: Impact of drivers and challenges
PART 19: Market trends
PART 20: Vendor landscape
PART 21: Appendix
PART 22: Explore Technavio
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.